Drug Profile
Laronidase - BioMarin/Sanofi
Alternative Names: Aldurazyme; Alpha-L-iduronidase; BM 101; JC 0498; rh alpha-L-iduronidaseLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator BioMarin Pharmaceutical; Genzyme Corporation
- Developer BioMarin Pharmaceutical; Sanofi; University of California at Los Angeles
- Class Glycoside hydrolases; Recombinant fusion proteins
- Mechanism of Action Iduronidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Mucopolysaccharidosis I
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Mucopolysaccharidosis-I(In children) in USA (Intrathecal, Injection)
- 08 Aug 2017 Launched for Mucopolysaccharidosis I in Russia and Hong Kong (IV) before August 2017
- 15 Feb 2017 Interim pharmacodynamics data from a trial in mucopolysaccharidosis type I (Hurler syndrome) released by Sanofi Genzyme